AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 102 min read$CYTK

Blum Robert I sold $576K of CYTK

Blum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $76.76 ($0.58M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blum Robert I
Published Aug 10, 2026, 9:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CYTK
Neutral
medium confidence
Mentioned
$CYTK
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

The newest disclosed fact is the same-day open-market sale of 7,500 shares at $76.76, with holdings after the transaction of 377,820 shares.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 designation generally limits fundamental interpretation.

03

What to watch

The filing does not state tax, diversification, or personal liquidity needs; without context on prior sales cadence, signal strength is limited.

Relevance 4/10Novelty 3/10Timing: filed on 2026-08-10, same day as the reported sale

Background

This is an SEC Form 4 insider transaction for Cytokinetics, Inc. (CYTK) by CEO Robert Blum.

Company-level read

Ticker impact

$CYTKNeutralMedium confidence
Context

CYTOK insider Form 4 shows CEO Robert Blum sold 7,500 shares at $76.76 on 2026-08-10 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any reaction would be sentiment-driven rather than fundamentals.

Evidence & confidence

Form 4 discloses the transaction size and price, but the presence of a 10b5-1 plan typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

No clear sector read-through from a single 10b5-1 insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales under 10b5-1 can be purely liquidity-driven and may not reflect bearish expectations.

Key entities

  • issuer
    CYTOKINETICS INC

    Company whose insider transaction is disclosed on Form 4.

  • insider
    Blum Robert I

    President and CEO who sold shares under a Rule 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

AUG 14
$CAPRMedAI 8/10

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

Capricor Therapeutics shares rose over 60% after CEO Linda Marbán said the FDA is willing to review an amended deramiocel submission for Duchenne muscular dystrophy, with an Aug. 22 decision deadline. Cytokinetics sued Bristol Myers Squibb over patents tied to Myqorzo. Valneva gained after EMA accepted a Pfizer vaccine application. Other updates covered funding, licensing, and drug availability.

finance.yahoo.com4 min
AUG 13
$CYTKMedAI 8/10

Cytokinetics (CYTK) Q2 2026 Earnings Call Transcript

Cytokinetics (CYTK) reported Q2 2026 revenue of $28.6M, down from $66.8M in 2025 due to fewer Bayer milestone payments, with MYQORZO net product revenue of $25.3M. Cash and investments were $1.7B after a May offering. Operating expense guidance was raised to $860M-$890M; net loss was $198.8M. MYQORZO new-to-brand share exceeded 40% in June.

fool.com10 min
AUG 6
$CYTKMedAI 8/10

CYTOKINETICS INC (CYTK): Results of Operations and Financial Condition

CYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cytk-ex99_1.htm EX-99.1 EX-99.1 Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Sup

SEC EDGAR 8-K6 min
JUL 30
$CYTKMedAI 8/10

Cytokinetics Secures MHRA Marketing Authorization For MYQORZO In OHCM

Cytokinetics (CYTK) said the UK MHRA granted marketing authorization for MYQORZO (aficamten) to treat adults with obstructive hypertrophic cardiomyopathy, NYHA class II-III. NICE issued positive guidance for eligible patients in England and Wales. Approval cited SEQUOIA-HCM Phase 3 results, with peak oxygen uptake improving vs placebo (1.8 vs 0.0 mL/kg/min, p<0.001).

rttnews.com4 min
JUL 30
$CYTKMedAI 8/10

Cytokinetics' cardiomyopathy drug cleared for NHS use

Cytokinetics said the UK MHRA and NICE cleared its cardiomyopathy drug Myqorzo (aficamten) for NHS use as an add-on to standard therapy in adults with NYHA class II-III obstructive hypertrophic cardiomyopathy. NICE required cost parity with Bristol Myers Squibb’s Camzyos. Myqorzo made about $5m in Q1 sales; Camzyos $314m.

pharmaphorum.com4 min
JUL 24
$CYTKMed

What Makes Cytokinetics' MYQORZO Launch a Game Changer

Cytokinetics (CYTK) is commercializing MYQORZO (aficamten), approved for symptomatic obstructive hypertrophic cardiomyopathy in the U.S., Europe, and China. The U.S. launch began in January 2026 and Europe is planned for Germany in Q2 2026. In 2025, revenue rose to $88.0M and net loss widened to $784.9M, while cash was about $1.22B.

kavout.com6 min